A treatment pioneered at the University of Pittsburgh Center for Vaccine Research (CVR) is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called “superbugs” resistant to almost all existing antibiotics, which plague hospitals and nursing homes.
The findings, announced online in the journal Antimicrobial Agents and Chemotherapy and funded by the National Institutes of Health, provide a needed boost to the field of antibiotic development, which has been limited in the last four decades and outpaced by the rise of drug-resistant bacterial strains.
“Very few, if any, medical discoveries have had a larger impact on modern medicine than the discovery and development of antibiotics,” said senior author Ronald C. Montelaro, Ph.D., professor and co-director of Pitt’s CVR. “However, the success of these medical achievements is being threatened due to increasing frequency of antibiotic resistance. It is critical that we move forward with development of new defenses against the drug-resistant bacteria that threaten the lives of our most vulnerable patients.”
Each year in the U.S., at least 2 million people are infected with drug-resistant bacteria, and at least 23,000 die as a direct result of these infections, according to the U.S. Centers for Disease Control and Prevention.
On the tail end of HIV surface protein, there is a sequence of amino acids that the virus uses to “punch into” and infect cells. Dr. Montelaro and his colleagues developed a synthetic and more efficient version of this sequence – called engineered cationic antimicrobial peptides, or “eCAPs”—that can be chemically synthesized in a laboratory setting.< The team tested the two leading eCAPs against a natural antimicrobial peptide (LL37) and a standard antibiotic (colistin), the latter being used as a last-resort antibiotic against multidrug resistant bacterial infections. The scientists performed the tests in a laboratory setting using 100 different bacterial strains isolated from the lungs of pediatric cystic fibrosis patients of Seattle Children’s Hospital and 42 bacterial strains isolated from hospitalized adult patients at UPMC.
The natural human antimicrobial peptide LL37 and the colistin drug each inhibited growth of about 50 percent of the clinical isolates, indicating a high level of bacterial resistance to these drugs. In marked contrast, the two eCAPS inhibited growth in about 90 percent of the test bacterial strains.
The Latest on: Antibiotic-Resistant Superbugs
via Google News
The Latest on: Antibiotic-Resistant Superbugs
- Health officials worried pandemic may be contributing to spike in antibiotic-resistant 'superbugs'on January 21, 2021 at 3:51 pm
A new study published in the Clinical Infectious Diseases journal analyzed thousands of hospitalized kids across the country who had been prescribed antibiotics in 2016 and 2017. It found 26% either ...
- CBD could be used to treat anti-biotic resistant superbugson January 21, 2021 at 1:31 pm
It's been touted as a natural treatment for depression, anxiety, migraines, and even conditions like epilepsy. But new research shows that CBD could do even more as a potential new class of antibiotic ...
- Irish soil can offer more hope in fight against antibiotic resistance, researchers showon January 20, 2021 at 4:00 pm
Scientists who highlighted the bug-busting properties of bacteria in Northern Irish soil have made another exciting discovery in the quest to discover new antibiotics.
- Fighting antibiotic resistant superbugs with viruseson January 19, 2021 at 2:41 pm
There's been advances in the fight to combat antibiotic resistant superbugs. One of the Australian scientists at the forefront of this research Jeremy Barr of Monash University talks to Jesse about ...
- Ineos donates £100m to launch Oxford university antibiotics instituteon January 18, 2021 at 10:03 pm
Researchers will seek to develop new drugs for animals and humans, as well as promote more responsible use of the antibiotics we have, following a rise in antibiotic-resistant "superbugs".
- Oxford university given £100m to fight antibiotic-resistant superbugson January 18, 2021 at 2:56 pm
Researchers will seek to develop new drugs for animals and humans, as well as promote more responsible use of the antibiotics we have, following a rise in antibiotic-resistant "superbugs". It is ...
- Phage therapy offers hope in fight against antibiotic resistance and superbugson January 14, 2021 at 8:42 am
As doctors become increasingly concerned about antibiotic resistance, which is predicted to cause millions of deaths each year by 2050, some researchers are looking in interesting places for help.
- Superbugs have an arsenal of defences — but we’ve found a new way around themon January 13, 2021 at 3:32 pm
Researchers have not discovered any new antibiotics in decades. But our new research, published today in Nature Microbiology, has found a way to give a second wind to the antibiotics we do have. It ...
via Bing News